CN104968673B - 融合多肽及使用方法 - Google Patents

融合多肽及使用方法 Download PDF

Info

Publication number
CN104968673B
CN104968673B CN201480003114.XA CN201480003114A CN104968673B CN 104968673 B CN104968673 B CN 104968673B CN 201480003114 A CN201480003114 A CN 201480003114A CN 104968673 B CN104968673 B CN 104968673B
Authority
CN
China
Prior art keywords
seq
sequence
il28b
amino acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480003114.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104968673A (zh
Inventor
刘宏宇
赵明治
孙赫彤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosit Sole Biotechnology Beijing Co ltd
Original Assignee
Prosit Sole Biotechnology Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosit Sole Biotechnology Beijing Co ltd filed Critical Prosit Sole Biotechnology Beijing Co ltd
Priority to CN201811243025.9A priority Critical patent/CN109293782A/zh
Publication of CN104968673A publication Critical patent/CN104968673A/zh
Application granted granted Critical
Publication of CN104968673B publication Critical patent/CN104968673B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201480003114.XA 2014-01-08 2014-01-08 融合多肽及使用方法 Active CN104968673B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811243025.9A CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/070328 WO2015103749A1 (en) 2014-01-08 2014-01-08 Fusion polypeptides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811243025.9A Division CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Publications (2)

Publication Number Publication Date
CN104968673A CN104968673A (zh) 2015-10-07
CN104968673B true CN104968673B (zh) 2018-11-02

Family

ID=53523446

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480003114.XA Active CN104968673B (zh) 2014-01-08 2014-01-08 融合多肽及使用方法
CN201811243025.9A Pending CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811243025.9A Pending CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Country Status (5)

Country Link
US (2) US10246501B2 (cg-RX-API-DMAC7.html)
EP (2) EP3092248B1 (cg-RX-API-DMAC7.html)
JP (1) JP6730926B2 (cg-RX-API-DMAC7.html)
CN (2) CN104968673B (cg-RX-API-DMAC7.html)
WO (1) WO2015103749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092248B1 (en) 2014-01-08 2021-06-23 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
JP2019107021A (ja) * 2019-03-05 2019-07-04 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
JP7741108B2 (ja) * 2020-05-27 2025-09-17 杭州先▲為▼▲達▼生物科技有限公司 インターロイキン２９変異体タンパク質
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
CN115385998B (zh) * 2021-04-13 2025-08-05 杭州先为达生物科技股份有限公司 稳定的iii型干扰素蛋白及其融合蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219796C (zh) * 1996-04-12 2005-09-21 佛罗里达大学 干扰素－τ多肽的N－末端氨基酸序列的应用
CN101031316A (zh) * 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
CN101918440A (zh) * 2007-09-20 2010-12-15 联邦科学技术研究组织 新的禽类细胞因子及编码其的遗传序列

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
DK1717316T3 (da) 2000-06-30 2008-12-08 Zymogenetics Inc Allelisk variant af interferon-lignende protein Zcyto21
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PT2251353E (pt) * 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
CA2574564C (en) * 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US7589179B2 (en) * 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
EP2296691A1 (en) * 2008-06-05 2011-03-23 ZymoGenetics, L.L.C. Use of pegylated type iii interferons for the treatment of hepatitis c
WO2010045261A1 (en) * 2008-10-13 2010-04-22 Zymogenetics, Llc Single chain fc type iii interferons and methods of using same
CA2850509C (en) 2011-10-14 2023-08-01 President And Fellows Of Harvard College Sequencing by structure assembly
WO2013087727A1 (en) * 2011-12-12 2013-06-20 Institut Pasteur New efficient interferon-based treating methods
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
EP3092248B1 (en) 2014-01-08 2021-06-23 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219796C (zh) * 1996-04-12 2005-09-21 佛罗里达大学 干扰素－τ多肽的N－末端氨基酸序列的应用
CN101031316A (zh) * 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
CN101918440A (zh) * 2007-09-20 2010-12-15 联邦科学技术研究组织 新的禽类细胞因子及编码其的遗传序列

Also Published As

Publication number Publication date
JP2017503505A (ja) 2017-02-02
EP3092248A1 (en) 2016-11-16
WO2015103749A1 (en) 2015-07-16
US11242371B2 (en) 2022-02-08
CN109293782A (zh) 2019-02-01
US20190382461A1 (en) 2019-12-19
EP3092248B1 (en) 2021-06-23
EP3954714A1 (en) 2022-02-16
US10246501B2 (en) 2019-04-02
JP6730926B2 (ja) 2020-07-29
CN104968673A (zh) 2015-10-07
EP3092248A4 (en) 2017-06-28
US20170022259A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
CN104968673B (zh) 融合多肽及使用方法
ES2553419T3 (es) Expresión de IL1RAP en células de leucemia mieloide aguda y crónica
Kang et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma
CN109072232A (zh) 用于提供单链rna的方法
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2006031811A3 (en) Glycopegylated interferon alpha
EP4295917A2 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2017529326A5 (cg-RX-API-DMAC7.html)
CN107106655A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
CN1269013A (zh) 呈递多个活性部分的分子
US20240026317A1 (en) PAN-RAS mRNA CANCER VACCINES
JP2024516613A (ja) 肝臓細胞への薬物送達のための環状ペプチド－Ｎ－アセチルガラクトサミン（ＧａｌＮＡｃ）コンジュゲート
Agyei et al. Peptides for biopharmaceutical applications
JP2024540977A (ja) ジスルフィドオリゴ糖化合物及び複合体
TW200938546A (en) Triazolotriazines and triazolopyrazines and their use
JP7712982B2 (ja) 融合ポリペプチドおよび使用方法
Bahrini et al. Development of a method that delivers drugs to enveloped viruses
CN102409056A (zh) 抑制血管生成相关基因序列
KR20020068260A (ko) β-2',3'-디데하이드로-2',3'-디데옥시-5-플루오로사이티딘에 의해 선택된 ＨＩＶ-1 돌연변이
CN105218660B (zh) 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用
US20240374697A1 (en) MULTIPLEXED TP53 AND PAN-RAS mRNA CANCER VACCINES
HK40104832A (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
Opdenakker et al. Applications of glycobiology: biological and immunological effects of a chemically modified amylose-derivative
Lushnikova et al. Novel approaches for overcoming of tumor drug resistance by polyvalent cationic peptides
Shackel et al. Snipping away at hepatitis C

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant